Accelerated single cell seeding in relapsed multiple myeloma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32680998.
- Also identified by DOI 10.1038/s41467-020-17459-z and PMC identifier 7368016.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Multiple myeloma (MM) progression is characterized by the seeding of cancer cells in different anatomic sites. To characterize this evolutionary process, we interrogated, by whole genome sequencing, 25 samples collected at autopsy from 4 patients with relapsed MM and an additional set of 125 whole exomes collected from 51 patients. Mutational signatures analysis showed how cytotoxic agents introduce hundreds of unique mutations in each surviving cancer cell, detectable by bulk sequencing only in cases of clonal expansion of a single cancer cell bearing the mutational signature. Thus, a unique, single-cell genomic barcode can link chemotherapy exposure to a discrete time window in a patient's life. We leveraged this concept to show that MM systemic seeding is accelerated at relapse and appears to be driven by the survival and subsequent expansion of a single myeloma cell following treatment with high-dose melphalan therapy and autologous stem cell transplant.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Clonal Evolution
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
- Neoplasm Recurrence, Local